Truist analyst Les Sulewski raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $65 from $62 and keeps a Hold rating on the shares ...

Is ANI Pharmaceuticals (ANIP) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this ...

Here are four stocks that made it through the screen: ANI Pharmaceuticals represents a compelling investment opportunity in 2025 as it strategically strengthens its Rare Disease portfolio and ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is ANI Pharmaceuticals (ANIP) one of those stocks right now? A ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Geron (GERN – Research Report), Genmab (GMAB – Research ...

U.S. stock markets are witnessing extreme volatility in April due to the Trump administration's tariffs on imported products from around the world. The baseline tariff of 10% was imposed on all ...

ANI Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. ANIP provides ...